Andrew Skora, PhD

Head of Research and Development and Co-founder AbVir Biotherapeutics

Dr. Andrew Skora brings over 15 years of experience in biologics development. He began his career as a postdoctoral researcher in the Vogelstein Lab at Johns Hopkins, where he developed MANAbody technology, the cornerstone for Clasp Therapeutics, which recently secured a $150 million Series A funding round. Dr. Skora refined his expertise in antibody engineering at Eli Lilly, where he led teams advancing antibody therapies from discovery through IND-enabling studies. He contributed to multiple biologics for oncology and neurology and supported the development of bamlanivimab, the first anti-COVID-19 biologic authorized for use. At Viracta Therapeutics, Dr. Skora, as Senior Director, led clinical biomarker strategies and managed the developability testing of the antibodies central to AbVir’s mission.